Riociguat in children with pulmonary arterial hypertension: the PATENT-CHILD study
Riociguat, a soluble guanylate cyclase stimulator, is approved for treatment of adults with pulmonary arterial hypertension (PAH). The safety, tolerability, and pharmacokinetics (PK) of oral riociguat in a pediatric population with PAH was assessed in PATENT-CHILD (NCT02562235), a multicenter, singl...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
01 September 2022
|
| In: |
Pulmonary circulation
Year: 2022, Volume: 12, Issue: 3, Pages: 1-12 |
| ISSN: | 2045-8940 |
| DOI: | 10.1002/pul2.12133 |
| Online Access: | Resolving-System, lizenzpflichtig, Volltext: https://doi.org/10.1002/pul2.12133 Verlag, lizenzpflichtig, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1002/pul2.12133 |
| Author Notes: | Humberto García Aguilar, Matthias Gorenflo, D. Dunbar Ivy, Shahin Moledina, Biagio Castaldi, Hidekazu Ishida, Paweł Cześniewicz, Jacek Kusa, Oliver Miera, Joseph Pattathu, Ken-Pen Weng, Laszlo Ablonczy, Christian Apitz, Marta Katona, Kenichi Kurosaki, Tomas Pulido, Hiroyuki Yamagishi, Kazushi Yasuda, Galia Cisternas, Melanie Goth, Susanne Lippert, Anna Radomskyj, Soundos Saleh, Stefan Willmann, Gabriela Wirsching, Damien Bonnet, Maurice Beghetti |
| Summary: | Riociguat, a soluble guanylate cyclase stimulator, is approved for treatment of adults with pulmonary arterial hypertension (PAH). The safety, tolerability, and pharmacokinetics (PK) of oral riociguat in a pediatric population with PAH was assessed in PATENT-CHILD (NCT02562235), a multicenter, single-arm, 24-week, open-label, Phase 3 study. |
|---|---|
| Item Description: | Gesehen am 29.11.2022 |
| Physical Description: | Online Resource |
| ISSN: | 2045-8940 |
| DOI: | 10.1002/pul2.12133 |